Physician profile
Eva Magiros
NPI 1033168091
$2,139.28
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $221 · 2021: $548 · 2022: $606 · 2023: $491 · 2024: $35.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $514.57 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $460.15 | 2021-2023 | Verquvo |
| Pfizer INC. | $281.12 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $178.63 | 2019-2022 | |
| Abbott Laboratories | $153.57 | 2019-2023 | Quadra Assura |
| Amgen INC. | $129.32 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $110.27 | 2020-2022 | |
| Esperion Therapeutics, INC. | $93.93 | 2020-2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $46.95 | 2022-2023 | Eliquis |
| Gilead Sciences, INC. | $41.21 | 2019 | |
| Boston Scientific Corporation | $34.55 | 2022 | |
| Itamar Medical INC | $22.21 | 2023 | Watchpatone |
| Kiniksa Pharmaceuticals, LTD. | $16.58 | 2021 | |
| Silk Road Medical, INC. | $15.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2020 | |
| Medtronic Vascular, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Magiros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.